Insider · CIK 0001827584
Seshadri Neervannan
Files at TARS (Tarsus Pharmaceuticals, Inc.). First filing Mar 5, 2026, latest Sep 9, 2026.
Seshadri Neervannan files SEC Form 4 as COO at TARS (Tarsus Pharmaceuticals, Inc.). Since Mar 5, 2026, Seshadri Neervannan has reported 0 open-market buys worth $0 and 4 open-market sells worth $2.0M, the latest filed on Sep 9, 2026.
A track record needs three past buys with six months of prices behind them; Seshadri Neervannan has 0, so none is measured yet.
The newest scored trade: sold $388k of TARS on Sep 4, 2026, filed Sep 9, 2026, scored 31 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 4 sells worth $2.0M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TARS: Tarsus Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 31Weak | Tarsus Pharmaceuticals, Inc. | $388k 4,564 shares | -5% | - | |
| 27Weak | Tarsus Pharmaceuticals, Inc. | $200k 2,989 shares | -3% | +66% from low-22% from high | |
| 62Notable | Tarsus Pharmaceuticals, Inc. | $772k 11,324 shares | -12% | +80% from low-15% from high | |
| 40Moderate | Tarsus Pharmaceuticals, Inc. | $641k 8,366 shares | -11% | +96% from low-8% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 20, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 2,435 0.01% of outstanding | $122k | Mar 20, 2025 | $241k |
| Mar 19, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 2,543 0.01% of outstanding | $121k | Mar 19, 2025 | $121k |
| Mar 18, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 2,605 0.01% of outstanding | $121k | Mar 18, 2025 | none |
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -4,564 | $85.00 | $388k | 78,532 | 34 d ago |
| Mar 20, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -2,989 | $66.75 | $200k | 82,791 | Mar 24, 2026 |
| Mar 17, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -3,125 | $69.42 | $217k | 93,979 | Mar 19, 2026 |
| Mar 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -3,610 | $68.71 | $248k | 90,369 | Mar 19, 2026 |
| Mar 19, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,589 | $67.00 | $307k | 85,780 | Mar 19, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +26,287 | - | - | 97,104 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -5,097 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -8,148 | $0.00 | $0 | 8,148 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -8,020 | $0.00 | $0 | 16,040 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -5,022 | $0.00 | $0 | 15,067 | Mar 17, 2026 |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +27,310 | $0.00 | $0 | 27,310 | Mar 9, 2026 |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +17,161 | $0.00 | $0 | 17,161 | Mar 9, 2026 |
| Mar 4, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -8,366 | $76.67 | $641k | 70,817 | Mar 5, 2026 |
| Dec 16, 2025 | TARS Tarsus Pharmaceuticals, Inc. | GGift Common Stock | -950 | $0.00 | $0 | 79,183 | Dec 18, 2025 |
| Dec 16, 2025 | TARS Tarsus Pharmaceuticals, Inc. | GGift Common Stockindirect: By daughter | +475 | $0.00 | $0 | 475 | Dec 18, 2025 |
Questions about Seshadri Neervannan
Answered from the filings on this page, as of the latest one.
Is Seshadri Neervannan buying or selling?
In the last 12 months Seshadri Neervannan reported 0 open-market buys worth $0 and 4 open-market sells worth $2.0M on SEC Form 4; the latest was sold $388k of TARS on Sep 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Seshadri Neervannan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Seshadri Neervannan has 0.
Where does Seshadri Neervannan file Form 4?
Seshadri Neervannan has filed Form 4 at TARS (Tarsus Pharmaceuticals, Inc.) as Chief Operating Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.